Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-beta-naltrexol-hydroxybupropion codrug
- Development stage
- Preclinical
- Lead developer
- University of Kentucky
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
CB-NTXOL-BUPOH is a transdermal codrug composed of 6-beta-naltrexol and hydroxybupropion, linked via a carbonate bond. 6-beta-naltrexol is the primary active metabolite of naltrexone and serves as a potent mu-opioid receptor antagonist, while hydroxybupropion is an active metabolite of bupropion that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and a nicotinic acetylcholine receptor antagonist. The codrug is designed to improve the percutaneous absorption of these agents for the simultaneous treatment of alcohol dependence and tobacco addiction. By utilizing a transdermal delivery system, the formulation aims to provide steady-state plasma concentrations, reduce first-pass metabolism, and improve patient compliance in treating comorbid substance use disorders.
- Other names
- 6-beta-naltrexol-hydroxybupropion codrug6-beta-naltrexol hydroxybupropion carbonate codrugCB-NTXOL-BUPOH
02
Targets
DAT (Dopamine plasma membrane transport protein)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on 6-beta-naltrexol-hydroxybupropion codrug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-beta-naltrexol-hydroxybupropion codrug.